A 44-year-old man, who had a history of myocardial infarction (MI) due to thrombotic occlusion of right coronary artery (RCA) aneurysm, visited emergency department presenting with ST-segment elevation myocardial infarction (STEMI). The patient had been on oral anticoagulant therapy (warfarin) from the first thrombotic event, but the medication had been recently changed to aspirin 4 months before the second event. Emergent coronary angiography revealed thrombotic total occlusion of RCA with heavy thrombotic burden from middle RCA to the ostium of the posterior descending branch. Combination pharmacotherapy was performed with anticoagulants (heparin), fibrinolytics (urokinase), and Glycoprotein IIb/IIIa antagonists (abciximab), in addition to mechanical thrombosuction. However, on hospital day 2, the patient complained recurrent chest pain and again underwent coronary angiography, which revealed distal embolization of large thrombus to the posterior lateral branch. Coronary flow was recovered after repeated mechanical thrombosuction was performed. This case has shown the importance of aggressive combination drug therapy, accompanied by mechanical thrombosuction in patient with myocardial infarction due to thrombotic occlusion of coronary artery aneurysm and the importance of unceasing life-long anticoagulant therapy in those particular patients.
INTRODUCTION
Coronary artery aneurysm is a rare disease characterized by an abnormal dilatation (diameter >50% of the normal adjacent segments) of localized or diffuse portion of the coronary artery. The prevalence has been reported to vary between 0.3% to 4.9% in several large studies. 1, 2 It is most commonly found in right coronary artery (RCA) and less frequently found in left coronary artery and has been known that the main cause of aneurysm is atherosclerosis in adult population and Kawasaki disease in both children and adolescents. 1 Pathophysiology of the media of the blood vessel plays a major role in progression of coronary artery aneurysm 2 that eventually leads to myocardial ischemic events, such as coronary artery thrombosis, distal embolization, rupture or vasospasm. 3 We experienced a case of ST-segment elevation myocardial infarction due to coronary artery thrombosis after warfarin interruption in a patient with a large coronary aneurysm. Here, we report this case with a review of the pertinent literature.
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CASE REPORT
A 44-year-old man, who had a history of myocardial infarction (MI) due to thrombotic occlusion of a large RCA aneurysm 16 months ago (Fig. 1 (Fig. 2C) , which was similar finding to his first MI event (Fig. 1A and 1B dilatation (maximum diameter of 7.5 mm) was observed (Fig. 3) . The patient was discharged without any further complications and coronary computed tomography angiography (CCTA) was performed 6 months later that revealed no residual thrombus or further enlargement of aneurysm compared to previous CCTA (Fig. 4) . Currently, the patient is receiving life-long anticoagulant therapy with warfarin.
DISCUSSION
Although the precise mechanism leading to the development of aneurysm in the coronary circulation is not well established, genetic predisposition, common risk factors for coronary artery disease, direct vessel injury and abnormal vessel wall metabolism are considered to play important role. 1 Atherosclerosis accounts for approximately 50% of all coronary artery aneurysms whether it is by poststenotic dilatation or by direct arterial injury, and Kawasaki disease is the other well-known cause.
1,2
In our case, although patient was somewhat young and plaque burden was not so high, when it considered that there was atherosclerotic plaque in proximal RCA and thereafter aneurysmal dilatation was observed distally on CCTA, it would be much proper that atherosclerosis and poststenotic dilatation would be a major pathophysiology of coronary aneurysm which was also confirmed by IVUS and CCTA ( Fig. 3 and 4) . In Kawasaki disease, similar to atherosclerosis, the main cause of death is also myocardial infarction secondary to thrombosis in aneurysm or A B C A B www.lipid.or.kr stenosis. 4 The complication of coronary artery aneurysm may be fatal such as thrombosis or rupture; however the optimal treatment options still remained controversial including anticoagulants, covered stents, reconstruction, resection and exclusion with bypass. 5 Our case has shown the therapeutic challenges in patients with large intracoronary thrombus presented with acute myocardial infarction and also embolized distally while treatment. We made every effort to dissolve the heavy thrombus in aneurysm using both pharmacotherapy and mechanical intervention and combination pharmacological regimens contain clopidogrel, intracoronary glycoprotein IIb/IIIa-receptor antagonist (abciximab), intravenous heparin and intracoronary/ intravenous thrombolytic agent (urokinase). 6, 7 There were a small randomized study showed that the intracoronary bolus administration of abciximab in patients undergoing primary PCI was superior to the standard intravenous treatment with respect to infarct size, extent of microvascular obstruction and perfusion 8 and a larger-scale randomized trial demonstrated that a low-dose intracoronary administration of streptokinase immediately after primary PCI was effective in significantly limiting long-term infarct size and preserving left ventricular volumes and functions 9 and there was a study similar to our case that a direct intracoronary administration of urokinase followed by abciximab treatment significantly reduced the thrombotic burden without increasing the risk of bleeding in 12 patients. 10 As we showed in our case, even though we used combined pharmacotherapy including clopidogrel, heparin, abciximab and urokinase, we could not prevent distal embolization. The incidence of distal embolization after percutaneous coronary intervention in patients with large thrombus burden was reported ranges between 6% and 15%.
11
Aspirin or warfarin is a common pharmacological treatment to prevent coronary thrombosis or ischemia in patients with coronary aneurysm, however there is a paucity of data and no randomized controlled study to determine their efficacy specifically in coronary aneurysm patients. In our case, it showed that long-term anticoagulation therapy with warfarin rather than aspirin alone would be more effective in patients with large coronary aneurysm who have a past history of distal embolization.
In conclusion, the current case highlights that both combination pharmacotherapy and mechanical intervention would be helpful for the management of patients with acute thrombotic occlusion of large coronary artery aneurysm, and in those patients life-long anticoagulant therapy should be needed to prevent second thromboembolic event.
